Sanbio Co., Ltd. (4592) Press Release
[Delayed] Notice Regarding Integration of AKUUGO(R) Manufacturing Operations in Japan Following Closure of Minaris’ U.S. Facility
Earlier from Sanbio
- [Delayed]Notice Concerning Recording of Non-operating Income and Deferred Income Taxes
- Consolidated Financial Results for the Three Months Ended April 30, 2026[Japanese GAAP]
- SanBio Obtains Marketing Approval for AKUUGO Suspension for Intracranial Implantation as a Therapeutic Agent for Improving Chronic Motor Paralysis from Traumatic Brain Injury
- SanBio Obtains Marketing Approval for “AKUUGO® Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)